Abstract
Adenocarcinoma of the salivary gland is a histology subtype of salivary gland carcinoma (SGC). Salivary gland carcinomas are rare tumors accounting for less than 5% of all cancers of the head and neck. Consequently, clinical data for systemic treatment including targeted treatment in metastatic SGC is limited and supported mainly by sporadic cases, retrospective reports, and early phase trials with a limited number of patients. We present a case of a patient who suffered from metastatic SGC, in whom novel molecular testing that uses immunohistochemical analysis and DNA microarray implied that the tumor would respond to anti-androgen treatment. The patient was given bicalutamide and achieved complete objective response.
Highlights
There are many histology types of salivary gland carcinoma (SGC), and each subtype has a different growth pattern and prognosis (Laurie & Licitra 2006)
Adenocarcinoma of the parotid gland indicates that the tumor originates from the gland cells; this is a general term and may be sub-classified according to morphological properties
We report a case of metastatic SGC, using a new molecular technology to identify suitable drugs targeting this type of tumor
Summary
There are many histology types of salivary gland carcinoma (SGC), and each subtype has a different growth pattern and prognosis (Laurie & Licitra 2006). Due to the rarity of this disease, there is no consensus on the role of systemic chemotherapy and the optimal treatment regimen in metastatic SGC cases (Laurie & Licitra 2006). We report a case of metastatic SGC, using a new molecular technology to identify suitable drugs targeting this type of tumor.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
